47,140 Shares in CEL-SCI Co. (NYSE:CVM) Purchased by Calton & Associates Inc.

Calton & Associates Inc. purchased a new position in CEL-SCI Co. (NYSE:CVM) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 47,140 shares of the company’s stock, valued at approximately $50,000. Calton & Associates Inc. owned approximately 0.09% of CEL-SCI at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of CVM. Vanguard Group Inc. grew its position in CEL-SCI by 5.5% during the 1st quarter. Vanguard Group Inc. now owns 2,193,327 shares of the company’s stock valued at $4,189,000 after purchasing an additional 113,703 shares during the last quarter. CVI Holdings LLC purchased a new stake in CEL-SCI during the 1st quarter valued at about $1,678,000. Renaissance Technologies LLC grew its position in CEL-SCI by 29.9% during the 2nd quarter. Renaissance Technologies LLC now owns 173,800 shares of the company’s stock valued at $202,000 after purchasing an additional 40,000 shares during the last quarter. Thoroughbred Financial Services LLC grew its position in CEL-SCI by 140.9% during the 2nd quarter. Thoroughbred Financial Services LLC now owns 136,761 shares of the company’s stock valued at $158,000 after purchasing an additional 80,001 shares during the last quarter. Finally, Cutter & CO Brokerage Inc. grew its position in CEL-SCI by 29.4% during the 2nd quarter. Cutter & CO Brokerage Inc. now owns 108,445 shares of the company’s stock valued at $126,000 after purchasing an additional 24,634 shares during the last quarter. 12.08% of the stock is currently owned by institutional investors.

CEL-SCI Stock Performance

Shares of CVM stock opened at $0.90 on Thursday. The company’s 50-day moving average is $1.07 and its 200 day moving average is $1.24. The company has a debt-to-equity ratio of 1.00, a quick ratio of 0.18 and a current ratio of 0.64. The company has a market capitalization of $48.98 million, a price-to-earnings ratio of -1.44 and a beta of 0.65. CEL-SCI Co. has a one year low of $0.89 and a one year high of $3.23.

CEL-SCI (NYSE:CVM) last announced its quarterly earnings results on Thursday, August 15th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.01). Sell-side analysts expect that CEL-SCI Co. will post -0.52 EPS for the current fiscal year.

CEL-SCI Company Profile

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers.